Hi all and FWIW a couple of days back the Pharma Letter posted an update on Rett Syndrome which includes the three drugs currently in development for treating it.
I have not seen the link elsewhere;
https://www.thepharmaletter.com/article/illuminating-rett-syndrome-update
Neuren’s Trofinetide is first, and potentially first off the rank too
.. “The FDA has set March 12, 2023 as an action date to decide whether trofinetide will be used for the treatment of RS. If approved, trofinetide would be the first ever FDA-approved treatment for this condition.”
Then Anavex 2-73 (with three trials in progress and expecting a fast tracked FDA approval).
And finally a summary on how Pfizer has pulled out Ketamine - a hallucinogenic drug it developed in 1963.
The study there was completed last November …. “and positive results have led to further considerations for a Phase II multi-center trial.”
cheers
2591 upcoming trials, page-20
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |